menu
    • menu
    [{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"12-LOX","graph1":"Hematology","graph2":"Phase I","graph3":"Veralox Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture","highestDevelopmentStatusID":"6","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VLX-1005","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Veralox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Veralox Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for VLX-1005

    Menu

    VLX-1005

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veralox Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Veralox Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005

                            Details : VLX-1005, a small molecule 12-LOX inhibitor, which is being evaluated for the treatment of heparin induced thrombocytopenia.

                            Brand Name : VLX-1005

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2024

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Veralox Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Veralox Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Hatteras Venture

                            Deal Size : $16.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

                            Details : The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

                            Brand Name : VLX-1005

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 16, 2021

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Hatteras Venture

                            Deal Size : $16.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth